Pipeline Progress at MEI Pharma - Analyst Blog


Shutterstock photo

MEI Pharma, Inc. ( MEIP ) announced that it has dosed the first patient in its phase II study on its pipeline candidate pracinostat, an oral histone deacetylase (HDAC) inhibitor, for the treatment of patients with myelodysplastic syndrome (MDS). The patients have either failed to respond or maintain a response to a hypomethylating agent (HMA) alone. MEI Pharma intends to evaluate the candidate in combination with Vidaza or Dacogen.

The primary endpoint of this study is the proportion of patients with complete remission (CR), partial remission and hematologic improvement (HI), while the secondary endpoints include overall response rate, CR rate, HI rate, duration of response, progression free survival, and overall survival. Top-line data from the study is expected in Dec 2014.

This is the third open-label phase II study on pracinostat. MEI Pharma continues to enroll patients in another phase II study of pracinostat in combination with Vidaza in frontline acute myeloid leukemia (AML). The top-line data is also expected in Dec 2014.

We note that in Jun 2013, MEI Pharma initiated a phase II study on pracinostat in combination with Vidaza for the treatment of MDS. MEI Pharma is on track to complete patient enrollment in this study in Jun 2014, with top-line data expected in Dec 2014.

We note that in Aug 2012, MEI Pharma acquired exclusive global rights to Pracinostat from S*BIO Pte Ltd, which is a privately-held biotechnology company.

MEI Pharma carries a Zacks Rank #4 (Sell). Better-ranked stocks include include Lannett Company, Inc. ( LCI ), WuXi PharmaTech (Cayman) Inc. ( WX ) and Endocyte, Inc. ( ECYT ). All the three stocks carry a Zacks Rank #1 (Strong Buy).

ENDOCYTE INC (ECYT): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

MEI PHARMA INC (MEIP): Free Stock Analysis Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: CR , ECYT , HI , HMA , LCI

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com